Zhiyong Deng
A5100635064- Thyroid Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Medical Imaging and Pathology Studies
- Astronomical and nuclear sciences
- Lung Cancer Research Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Nuclear physics research studies
- Nuclear Materials and Properties
- RNA modifications and cancer
- Pneumocystis jirovecii pneumonia detection and treatment
- Peptidase Inhibition and Analysis
- Liver Disease Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Liver physiology and pathology
- Atomic and Subatomic Physics Research
China General Nuclear Power Corporation (China)
2023
Background: An unmet need for more effective and affordable kinase inhibitors remains in patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) China, where only sorafenib is approved this indication. This study evaluated the 24-week objective response rate (ORR) to donafenib-a new, domestic multikinase inhibitor-in treatment of locally advanced or metastatic RAIR-DTC measurable lesions. Two dose regimens (300 mg twice daily vs. 200 daily) were used...
The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.This multicenter, double-blind, placebo-controlled, III enrolled 191 RAIR-DTC randomized a ratio 2:1 (300 mg twice daily,...
The yield distributions of neutron-induced fission actinides were calculated and evaluated by using the improved scission-point model with considering octupole deformation fragments. We studied influence on asymmetric yields fission. more probable scission configuration is pear-shaped heavy fragments rather than spherical shape. used to calculate peak charge neutron compared results experimental data. confirm that main mode indeed characterized...
<div>Abstract<p>Purpose: The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumour activity safety RAIR-DTC patients. Patients Methods: This multicenter, double-blind, placebo-controlled, III...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<div>AbstractPurpose:<p>The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.</p>Patients Methods:<p>This multicenter, double-blind,...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<div>Abstract<p>Purpose: The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumour activity safety RAIR-DTC patients. Patients Methods: This multicenter, double-blind, placebo-controlled, III...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<div>AbstractPurpose:<p>The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.</p>Patients Methods:<p>This multicenter, double-blind,...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
Radionuclide imaging of pulmonary cancer develops very rapidly in recent years. Its important value on the diagnosis, staging, monitoring recur and metastasis after treatment, judging curative effect prognosis has been demonstrated. Clinicians pay more attention to it than before. This present article introduces principle, clinical use, good bad points, progress situation 67Ga, 201Tl, 99Tcm, 18F their labelled compounds, which are commonly used clinical. And radionuclide neoplasm concerning...
The author reports a patient who was admitted due to ′pain in the lumbosacral region and bilateral lower limbs with limited activity for 1 year′. Based on clinical symptoms, laboratory tests, imaging examinations, bone marrow cell morphological postoperative pathology, diagnosed multiple myeloma, acute renal failure, hypercalcemia, hematopoietic dysfunction of marrow, pulmonary infection. Moreover, SPECT revealed diffuse uptake 99Tcm-MDP pulmonary. Relevant literature suggests that myeloma...
Abstract Background No available treatment existed in Chinese patients with progressive radioactive iodine–refractory differentiated thyroid cancer (RAIR-DTC) terms of both affordability and safety upon the initiation DIRECTION study. Donafenib is an oral tyrosine kinase inhibitor (TKI) superior efficacy over sorafenib hepatocellular carcinoma (HCC) phase III This study aimed to evaluate its antitumour activity RAIR-DTC patients. Methods The sequential II/III design as a whole protocol was...